Chapter title |
Adoptive T-Cell Immunotherapy.
|
---|---|
Chapter number | 15 |
Book title |
Epstein Barr Virus Volume 2
|
Published in |
Current topics in microbiology and immunology, January 2015
|
DOI | 10.1007/978-3-319-22834-1_15 |
Pubmed ID | |
Book ISBNs |
978-3-31-922833-4, 978-3-31-922834-1
|
Authors |
Gottschalk, Stephen, Rooney, Cliona M, Stephen Gottschalk, Cliona M. Rooney, Rooney, Cliona M. |
Abstract |
Epstein-Barr virus (EBV) is associated with a range of malignancies involving B cells, T cells, natural killer (NK) cells, epithelial cells, and smooth muscle. All of these are associated with the latent life cycles of EBV, but the pattern of latency-associated viral antigens expressed in tumor cells depends on the type of tumor. EBV-specific T cells (EBVSTs) have been explored as prophylaxis and therapy for EBV-associated malignancies for more than two decades. EBVSTs have been most successful as prophylaxis and therapy for post-transplant lymphoproliferative disease (PTLD) , which expresses the full array of latent EBV antigens (type 3 latency), in hematopoietic stem-cell transplant (HSCT) recipients. While less effective, clinical studies have also demonstrated their therapeutic potential for PTLD post-solid organ transplant and for EBV-associated malignancies such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, and nasopharyngeal carcinoma (NPC) that express a limited array of latent EBV antigens (type 2 latency). Several approaches are actively being pursued to improve the antitumor activity of EBVSTs including activation and expansion of T cells specific for the EBV antigens expressed in type 2 latency, genetic approaches to render EBVSTs resistant to the immunosuppressive tumor environment, and combination approaches with other immune-modulating modalities. Given the recent advances and renewed interest in cell therapy, we hope that EBVSTs will become an integral part of our treatment armamentarium against EBV-positive malignancies in the near-future. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 52 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 8 | 15% |
Student > Ph. D. Student | 7 | 13% |
Researcher | 6 | 12% |
Student > Master | 6 | 12% |
Student > Doctoral Student | 5 | 10% |
Other | 8 | 15% |
Unknown | 12 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 27% |
Agricultural and Biological Sciences | 9 | 17% |
Biochemistry, Genetics and Molecular Biology | 6 | 12% |
Immunology and Microbiology | 5 | 10% |
Nursing and Health Professions | 2 | 4% |
Other | 4 | 8% |
Unknown | 12 | 23% |